Form 4 for CGEN COMPUGEN LTD
Accepted 2026-04-13 16:04:34 ET · period of report 2026-04-07 · accession 0001178913-26-002089 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-04-13 16:04 | 2026-04-10 | CGEN | Levine Zurit | SVP, Business Development | M - OptEx | $1.03 | +3,125 | 32.5K | +11% | +$3,233 |
| DT | 2026-04-13 16:04 | 2026-04-10 | CGEN | Levine Zurit | SVP, Business Development | S - Sale+OE | $2.56 | -3,125 | 29.4K | -10% | -$8,012 |
| DMT | 2026-04-13 16:04 | 2026-04-10 | CGEN | Levine Zurit | SVP, Business Development | M - OptEx | $0.00 | -3,125 | 56.0K | -5% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2026-04-10 | M | A | 1,125 | $0.8292 | 30,500 | D | — | — | (F1) This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 23, 2025. |
| 2 | Common | Ordinary Shares | 2026-04-10 | M | A | 2,000 | $1.15 | 32,500 | D | — | — | (F1) This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 23, 2025. |
| 3 | Common | Ordinary Shares | 2026-04-10 | S | D | 3,125 | $2.56 | 29,375 | D | — | — | (F1) This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 23, 2025. (F2) The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.50 to $2.60 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 4 | Derivative | Share Option (right to buy) | 2026-04-10 | M | D | 1,125 | $0.00 | 5,625 | D | $0.8292 · — to 2032-11-09 | 1,125 Ordinary Shares | (F1) This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 23, 2025. (F3) This option vested 25% on December 31, 2023 and the remainder vested or vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer. |
| 5 | Derivative | Share Option (right to buy) | 2026-04-10 | M | D | 2,000 | $0.00 | 56,000 | D | $1.15 · — to 2033-08-03 | 2,000 Ordinary Shares | (F1) This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 23, 2025. (F4) This option vested 25% on September 30, 2024 and the remainder vested or vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer. |